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We show here high levels of expression and secretion
of the chemokine CXC ligand 5 (CXCL5) in the macro-
phage fraction of white adipose tissue (WAT). More-
over, we find that CXCL5 is dramatically increased
in serum of human obese compared to lean subjects.
Conversely, CXCL5 concentration is decreased in
obese subjects after a weight reduction program, or
in obese non-insulin-resistant, compared to insulin-
resistant, subjects. Most importantly we demonstrate
that treatment with recombinant CXCL5 blocks
insulin-stimulated glucose uptake in muscle in mice.
CXCL5 blocks insulin signaling by activating the
Jak2/STAT5/SOCS2 pathway. Finally, by treating
obese, insulin-resistant mice with either anti-CXCL5
neutralizing antibodies or antagonists of CXCR2,
which is the CXCL5 receptor, we demonstrate that
CXCL5 mediates insulin resistance. Furthermore
CXCR2/ mice are protected against obesity-
induced insulin resistance. Taken together, these
results show that secretion of CXCL5 by WAT resident
macrophages represents a link between obesity,
inflammation, and insulin resistance.
INTRODUCTION
White adipose tissue (WAT) is primarily involved in energy
storage in the form of triglycerides and energy release in theform of free fatty acids. However, WAT is no longer considered
only as a fat storage organ. Instead, WAT secrete numerous
factors that play a role in several physiological and pathological
processes including immunological response, angiogenesis,
growth and differentiation, atherosclerosis, hypertension,
glucose homeostasis, appetite regulation, and cancer (reviewed
in Ahima and Flier, 2000; Trujillo and Scherer, 2006). External
factors such as nutritional status, stress, physical exercise,
infection, or trauma will affect WAT biology through various
signaling pathways including growth factors and fatty acids. In
turn, WAT will then signal other organs in an endocrine manner,
thereby transmitting a metabolic, proliferative growth or a differ-
entiation response. Adipose tissue-derived factors are secreted
by the different cell compartments of WAT, such as adipocytes
or macrophages, and were initially characterized as regulators
of metabolic processes, such as regulation of food intake,
energy homeostasis, adipocyte differentiation, or insulin sensi-
tivity. Subsequently, it was found that adipose tissue-derived
factors could modulate inflammatory processes. These factors
include WAT-specific factors, such as leptin, adiponectin, and
well-known cytokines secreted by several cell types, such as
TNFa, IL-6, IL-8, IL-1, or monocyte chemoattractant protein-1
(MCP-1). Increased WAT mass, such as observed in obese
subjects, is correlated with chronic systemic inflammatory
response, demonstrated by increased infiltration of macro-
phages in WAT (Weisberg et al., 2003; Xu et al., 2003). This
inflammatory state results in the development of obesity-associ-
ated pathologies including atherosclerosis, hypertension, nonal-
coholic steatohepatitis, and insulin resistance. These obesity-
associated pathologies are the result, at least in part, of changes
in the secretion of adipose tissue-derived factors and illustratesCell Metabolism 9, 339–349, April 8, 2009 ª2009 Elsevier Inc. 339
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CXCL5 and Insulin ResistanceFigure 1. CXCL5 Is Expressed by WAT Resident Macrophages
(A) CXCL5 level was measured by ELISA assay in total protein extract of WAT, liver and muscle from 10-week-old C57Bl/6 mice (n = 4 mice). *p < 0.05, **p < 0.01,
***p < 0.001 here and in following figures or otherwise stated.
(B) WAT from 10-week-old C57Bl/6 mice (n = 4 mice) were incubated in KRBH buffer for 1 hr, 3 hr, or 22 hr. At each time point, secreted CXCL5 in medium was
analyzed by ELISA and normalized by DNA content in tissue.
(C) CXCL5 mRNA quantification by QPCR in different fractions of isolated human subcutaneous WAT as indicated. SVF: stromal vascular fraction. Quantification
of mRNA was normalized by the expression level of rS9, here and in the following figures.
(D and E) Quantification of relative CXCL5 mRNA levels at the indicated times of 3T3-L1 (D) or human preadipocyte (E) differentiation in three independents exper-
iments.
(F) aP2mRNA expression was analyzed by quantitative RT-PCR on 3T3L1 adipocytes differentiated with or without recombinant mouse CXCL5 (50ng/ml). Values
in (C), (D), (E), and (F) represent means ± SEM of three independents experiments.the link between inflammatory state and metabolic response
(Hotamisligil, 2006).
Chemokines are proinflammatory cytokines that stimulate
leukocyte chemoattraction and are produced in response to
infectious and other inflammatory stimuli by a number of different
cell types. To date more than 50 proinflammatory cytokines or
chemokines have been identified and have been classified into
four groups according to the location of the conserved cysteine
residues: CXCL, CCL, CL, and CX3CL (Zlotnik et al., 2006). These
chemokines specifically recruit different cell types to an inflam-
matory site. CXCL5 or epithelial neutrophil-activating peptide
(ENA-78) is a cytokine belonging to the family of chemokines
that is mainly implicated in the chemotaxis of inflammatory cells
through the generation of local concentration gradients (Walz
et al., 1991, 1997). It has been shown to be a recruiter of neutro-
phils and involved in their activation, through interaction with the
CXCR2 receptor. This C-X-C chemokine has been implicated in
pulmonary disease, lung cancer, arthritis, and other pathological
states (Walz et al., 1991; 1993; Wislez et al., 2004). In the present
study we show that CXCL5 is expressed at high levels in WAT, in
particular in the macrophage fraction. We further show that circu-
lating levels of CXCL5 are associated with human obesity and
insulin resistance, and demonstrate inhibitory effects of the cyto-
kine in insulin-induced glucose transport in muscle cells. Consis-340 Cell Metabolism 9, 339–349, April 8, 2009 ª2009 Elsevier Inc.tent with a role in insulin resistance, we show that treatment of
obese, insulin-resistant mice with either neutralizing anti-
CXCL5 antibodies or CXCR2 antagonists results in an overall
decrease in fasting glycemia, and improved insulin sensitivity.
Finally, we show that CXCR2 (/) mice are resistant to diet-
induced insulin resistance and diabetes.
RESULTS
CXCL5 Is Expressed by WAT Resident Macrophages
Global analysis of cytokine expression in insulin-sensitive tissues
highlighted the presence of high levels of CXCL5 protein expres-
sion in WAT in mice, compared to liver or muscle (Figure 1A), sug-
gesting that CXCL5 could be an adipose tissue-derived factor.
Consistent with this hypothesis, CXCL5 was found to be secreted
by WAT explants in culture (Figure 1B). Furthermore, fractionation
of human subcutaneous WAT by collagenase digestion showed
that the stromal vascular fraction (SVF) expressed higher levels
of CXCL5 than did mature adipocytes, as assessed by real-
time PCR analysis (Figure 1C). A more detailed analysis by immu-
noselective isolation demonstrated that the major contribution to
CXCL5 concentration was from macrophages from the SVF of
human WAT (Figure 1C). Isolation of specific cell types was vali-
dated with specific markers of each fraction (Table S1). The
Cell Metabolism
CXCL5 and Insulin ResistanceFigure 2. Obesity Increases CXCL5 Release from WAT and CXCL5 Systemic Level
(A) Quantification by ELISA methods of CXCL5 secretion by WAT explants from C57Bl/6 and db/db mice (n = 3) after 6 hr in incubation media. Results were
normalized by DNA content in tissue.
(B) Circulating CXCL5 levels were measured by ELISA methods in serum from male control C57Bl/6, db/db, ob/ob, and mice fed with a high-fat diet (n = 5).
(C) Circulating TNFa levels were measured by ELISA methods in serum from control C57Bl/6 mice and mice fed with a high-fat diet (HFD) for 12 weeks (n = 4).
(D) Quantification of CXCL5 concentration in serum, as measured by ELISA between normal lean (n = 41) and obese patients (n = 82).
(E) Quantification of CXCL5 concentration in serum, as measured by ELISA in response to body weight loss during a 4 week very-low calorie diet (VLCD) in
24 obese patients. Data are means ± SEM.observed high levels of expression in WAT could point to the
participation of CXCL5 in adipogenesis. To address the role of
CXCL5 in adipocyte differentiation, we first analyzed CXCL5
mRNA expression during this process. CXCL5 mRNA was highly
expressed in mouse and human preadipocytes, whereas its
expression progressively decreased during adipocyte differenti-
ation (Figures 1D and 1E). PPARg mRNA level is showed as
specific marker of adipocyte differentiation (Figure S1). This
result suggested that CXCL5 was not critical for adipogenesis.
To demonstrate this hypothesis the effects of recombinant
CXCL5 on 3T3-L1 preadipocyte differentiation were evaluated.
3T3-L1 cells differentiated into adipocytes, as measured by the
expression of the adipocyte marker aP2, regardless of the
absence or the presence of CXCL5 (Figure 1F). Altogether, these
results suggested that CXCL5 is an adipose tissue-derived factor
secreted by WAT macrophages.
CXCL5Expression andSecretion Is Increased inObesity
The inflammatory state associated with obesity includes macro-
phage infiltration inWAT and increasedcytokinesecretion by these
macrophages. Since it is expressed in WAT macrophages
(Figure 1C), we hypothesized that CXCL5 expression would beincreased in obesity. Consistent with this hypothesis CXCL5
secretion in WAT explants from obese db/db mice was markedly
increased compared to nonobese control mice (2.5-fold,
Figure 2A). Most interestingly, circulating serum CXCL5 concentra-
tion was increased 2-fold in obese ob/ob and db/db and high- fat
diet-fed mice compared to lean mice (Figure 2B). Interestingly,
TNFa levels were also increased in high-fat diet-fed mice
(Figure 2C). These results prompted us to analyze CXCL5 concen-
tration in human obese subjects. Similar to the results observed in
mice,CXCL5serumconcentrationwassignificantly increased inan
obese French population, compared to lean control subjects
(median : 1,545 [295–25,900] versus 970 [395–2,790] pg/ml, p =
0.025) (Figure 2D). Control subjectswere age and gender matched,
and the observed differences were independent of age and gender
as calculated by Wilcoxon-Mann-Whitney test (p = 0.19). As
expectedserum leptin levels were also increased in the obese pop-
ulation (from 12.37 ± 5.83 in lean to 119.87 ± 22.93 mg/l in obese).
Similar results were observed when an English cohort was
analyzed (Figure S2). To further demonstrate a positive correlation
between body weight and CXCL5-circulating levels, calorie-
restriction experiments were performed. Obese women were
subjected to a very low-calorie diet (VLCD, 800kcal/d) for a periodCell Metabolism 9, 339–349, April 8, 2009 ª2009 Elsevier Inc. 341
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CXCL5 and Insulin ResistanceFigure 3. CXCL5 Is Involved in Insulin Resistance
(A) Comparative expression of CXCR2 mRNA in WAT, liver, and muscle from 6-month-old C57Bl/6 mice (n = 3).
(B) 2-deoxy-glucose uptake in isolated soleus muscles from mice (n = 3). Muscle strips were incubated with or without recombinant CXCL5 (100 ng/ml) for 1 hr
before stimulation with insulin (107 M).
(C) Protein expression of phospho-Akt, and total Akt in whole cells lysates from isolated muscles (upper panel) described in (B) and from primary MEFs (lower
panel) as analyzed by western blotting with anti-phospho-Ser473-Akt and anti-Akt antibodies. Blot are representative of three independents experiments.
(D) Relative mRNA level of SOCS2 in primary MEFs treated or not with CXCL5 (300 ng/ml) and cotreated with or without Jak2 inhibitor (AG490 50mM) or CXCR2
inhibitor (SB225002 106 M).
(E) Protein expression of phospho-STAT5a/b and total STAT5 in whole cells lysates from primary MEFs treated with or without insulin (107 M) and/ or CXCL5
(300 ng/ml) as analyzed by western blotting with anti-phospho-Y694/Y699-STAT5a/b and anti-STAT5 antibodies. Blots are representative of two independents
experiments.
(F) Relative quantification of circulating CXCL5 concentration (fold) in mice (n = 10 per group) after 12 days treatment with 20 mg/Kg rosiglitazone (rosi) compared
to nontreated mice (control).
(G) CXCL5 serum concentration is increased in obese patients with insulin resistance (n = 30), compared to obese non-insulin-resistant subjects (n = 22). Insulin
resistance status was assessed by the HOMA index (non IR: HOMA% 2.6; IR: HOMA% 2.6).
(H) Quantification of CXCL5 concentration in serum, as measured by ELISA between normal lean (n = 9), lipodystrophic patients (n = 12) and obese patients
(n = 11). Data are means ± SEM.of 4 weeks (Vitkova et al., 2007). An average decrease of 7% in
body weight was observed during VLCD. Strikingly, the weight
loss is associatedwitha decrease of10%inserum CXCL5 concen-
tration (median: 2230 versus 2040 pg/ml, p = 0.006), suggesting
that CXCL5-circulating concentration is controlled by WAT
(Figure 2E).
CXCL5 Mediates Insulin Resistance
Some of the insulin-desensitizing effects observed during obesity
development are mediated by adipokines. The positive associa-
tion of CXCL5 concentration with obesity suggested that this
chemokine could be a mediator of insulin resistance. The biolog-
ical effects of CXCL5 are mediated through interaction with the
chemokine receptor CXCR2. To investigate the role of CXCL5
in insulin resistance, we first aimed to identify tissues that are
potentially responsive to CXCL5. Expression analysis in insulin-
sensitive tissues showed that CXCR2 mRNA was expressed at342 Cell Metabolism 9, 339–349, April 8, 2009 ª2009 Elsevier Inc.higher levels in muscle than in liver or WAT (Figure 3A). The phys-
iological effects of CXCL5 in muscle were next analyzed. Incuba-
tion of isolated soleus muscles with recombinant CXCL5 resulted
in a diminution of insulin-stimulated glucose transport in this
tissue (Figure 3B). This suggested a role of CXCL5 in mediating
insulin resistance. Strikingly, CXCL5 treatment inhibited insulin-
induced Akt phosphorylation (Figure 3C, from 10- to 6-fold),
which was consistent with the observed decrease in glucose
transport in CXCL5-treated muscles (Figure 3B). Similarly,
CXCL5 inhibited Akt phosphorylation also in primary cultures of
mouse embryonic fibroblasts (MEFs) (Figure 3C). A more in detail
analysis suggested that CXCL5 was inhibiting insulin signaling
through activation of the JAK/STAT pathway, and consequently
through increasing the expression of SOCS2, which is a known
inhibitor of the insulin receptor, and increasing the activity of
Stat5 signaling up to 2.5-fold (Figures 3D and 3E). Strikingly,
SOCS 2 regulation by CXCL5 is blunted by a Jak2 inhibitor,
Cell Metabolism
CXCL5 and Insulin ResistanceFigure 4. Inhibition of CXCL5 Action in Obese Mice Improves Insulin Sensitivity
(A–D) Fasting glucose (A and B) and insulin (C and D) in 18-week-old obese HFD fed mice (A–C) and 9-week-old db/db mice (B–D) after 7 days of treatment with
neutralizing antibody against CXCL5 (anti-CXCL5) or control IgG (cont IgG) (n = 10 mice per group).
(E–H) Glucose clearance after intraperitoneal injection of insulin (0.75 U/kg, E and F) or glucose (G and H) in animals treated with anti-CXCL5 or control IgG. For the
graph (E), (F), and (G), glucose values are relative to initial glucose levels. Area under the curve was analyzed (AUC). Data are means ± SEM.AG490, and by CXCR2 antagonist treatments (Figure 3D). From
these results we concluded that CXCL5 could block insulin
signaling in muscle through activation of the Jak/STAT/SOCS
pathway through the CXCR2 receptor. We attempted next to
demonstrate a positive correlation between insulin resistance
and serum CXCL5 concentration in mice. Obese db/db mice
were treated with the insulin-sensitizing drug rosiglitazone. This
resulted as expected in a decrease in glycemia (Figure S3).
Decreased circulating glucose concentration was significantly
associated with a 30% decrease in serum CXCL5 concentration
in rosiglitazone-treated mice (Figure 3F).
We next examined the relationship between CXCL5 and
insulin sensitivity in a population of obese subjects. The subjects
(n = 52) were stratified into two groups according to HOMA
values, as a measure of insulin resistance index. Clinical param-
eters of the subjects are summarized in Table S2. We found that
serum CXCL5 concentration was higher in insulin-resistant
compared to non-insulin-resistant obese subjects, suggesting
that CXCL5 circulating levels are causative of insulin resistance
in these subjects (Figure 3G; IR: 3960 pg/ml versus non IR:
3110 pg/ml, p = 0.021). Furthermore, we have analyzed CXCL5
serum levels in a human model of non-obese insulin resistance.
We show that lipodystrophic patients, who are insulin resistant,
do not have increased levels of CXCL5 (Figure 3H). We can
conclude from this data that it is CXCL5 that induces insulin
resistance, and not the opposite. Taken together these results
suggested that CXCL5 is involved in the development of insulin
resistance during obesity.Inhibition of CXCL5 Signaling in Insulin-Resistant Mice
Improves Insulin Sensitivity
To unequivocally demonstrate the participation of CXCL5 in
obesity-induced insulin resistance we analyzed the effects of
CXCL5 inhibition in two mice model of insulin resistance.
C57BL/6 mice rendered obese by feeding high-fat diet for
12 weeks, and obese db/db mice were treated every other day
with intraperitoneal injection of neutralizing anti-CXCL5 antibody
or control IgG. After 1 week of treatment, a significant decrease
in fasting glucose was observed in mice injected with anti-
CXCL5 compared to mice injected with control IgG (Figures 4A
and 4B). Anti-CXCL5-treated obese mice were more sensitive
to insulin as measured by fasted insulin level (Figures 4C and
4D) and by insulin tolerance test (Figures 4E and 4F). Moreover,
treatment with anti-CXCL5 improved glucose tolerance during
an intraperitoneal glucose tolerance test in both mouse models
of obesity (Figures 4G and 4H).
Since CXCL5 signaling is mediated by the CXCR2 receptor,
we next studied the impact of a selective antagonist of
CXCR2, SB225002, on insulin sensitivity. Obese C57BL/6 mice
were treated daily with intraperitoneal injection of SB225002
(100mg/kg) for 10 days. Similar to the effect of neutralizing anti-
body, SB225002 treatment also decreased fasting glucose and
insulin level (Figures 5A and 5B), and increased insulin sensitivity
and glucose homeostasis as demonstrated by insulin and
glucose tolerance tests (Figures 5C and 5D). No differences in
body weight or food intake were observed as a result of either
SB225002 or anti-CXCL5 antibody treatments, suggestingCell Metabolism 9, 339–349, April 8, 2009 ª2009 Elsevier Inc. 343
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CXCL5 and Insulin Resistancea direct rather than a secondary effect (Figures 4A–4C). Since
CXCL5 is secreted in normal mice, we tested the effect of the
treatments in these mice. Even in these SB225002- and anti-
CXCL5-treated lean mice a significant increase in glucose clear-
ance was observed (Figure S5B).
To unequivocally demonstrate the participation of the CXCL5-
CXCR2 signaling axis in insulin sensitivity, we next analyzed the
phenotype of CXCR2/mice. The most concluding observation
was the protection of CXCR2/mice to obesity-induced insulin
resistance (Figure 6). Fasting glucose concentration remained
normal in CXCR2/ mice fed a high-fat diet, compared to
CXCR2+/+ mice (Figure 6A). Surprisingly, an increase in fasted
insulin levels was observed, suggesting that the genetic deletion
of CXCR2 could also affect otherpathways (Figure 6B). Moreover,
no differences in body weight or food intake were observed
(Figures 6C and 6D), whereas improved insulin sensitivity and
glucose tolerance in both chow and high-fat diet CXCR2/
compared to +/+ mice were observed (Figures 6E and 6F). Inter-
estingly, genetic CXCR2 ablation or CXCR2 antagonist treatment
are more effective than CXCL5 blocking, suggesting that other
CXCR2 ligands could be involved in this pathway. Strikingly,
circulating levels of CXCL1 and CXCL2, which are also CXCR2
ligands, are increased in mice models of obesity, although to
a lesser extent than CXCL5. Taken together, these results show
that CXCL5 plays a major role in insulin resistance.
CXCL5 Is Regulated by TNFa
We finally analyzed the molecular mechanisms implicated in the
observed increase in CXCL5 expression in the macrophage frac-
tion of WAT. WAT secretes large amounts of TNFa in obese
states, suggesting that this cytokine could regulate the expres-
sion of CXCL5. This was shown by the observation that CXCL5
secretion by human WAT explants was increased upon treatment
Figure 5. Inhibition of CXCR2 Signaling Improves
Insulin Sensitivity
(A and B) Fasting glucose (A) and insulin (B) in 18-week-old
HFD fed mice after 9 days of treatment with CXCR2 antago-
nist, SB225002 (100 mg/kg), or vehicle (n = 10 mice per group).
(C and D) Glucose clearance after intraperitoneal injection of
insulin (0.75 U/kg) (C) or glucose (D) in animals treated with
SB225002 or vehicle. Area under the curve was analyzed
(AUC). Data are means ± SEM.
with TNFa for 24 hr (Figure 7A). TNFa is a key factor
regulating CXCL5 level in WAT since we demon-
strated that CXL5 mRNA expression is strongly
decreased in WAT from obeseob/obTNFa receptor
/ mice compared to the ob/ob mice (Figure 7B).
Furthermore, we showed in WAT explants from
mice that TNFa-induced CXCL5 secretion were
reduced by cotreatment with the PPARg agonist
rosiglitazone, which is known to antagonize the
effects of TNFa (Figure 7C). Similar results were
observed when THP-1 macrophages, instead of
WAT explants, were treated with TNFa (Figure 7D).
Moreover, increased CXCL5 secretion in response
to TNFa correlated to increased CXCL5 mRNA
expression in these cells (Figure 7E). Rosiglitazone
cotreatment of the cells also resulted in a reduction of TNFa pro-
secretory (Figure 7D) and mRNA stimulation effects (Figure 7E).
This suggested that TNFa regulation of CXCL5 expression is at
the transcriptional level. Computational analysis of the human
CXCL5 promoter sequence revealed the presence of several
NFkB binding sites located upstream of the transcription start
site, which could mediate the effects of TNFa. Transient transfec-
tion experiments using the CXCL5 promoter driving the expres-
sion of the luciferase gene demonstrated a 6.5-fold increase in
CXCL5promoter activity upon stimulation of the transfected cells
with TNFa (Figure 7F). Similar to that observed when mRNA levels
were analyzed (Figure 7E) the induction of CXCL5 promoter
activity by TNFa was reduced by rosiglitazone cotreatment in
cells cotransfected with PPARg (Figure 7F). To demonstrate
that the regulation of the CXCL5 promoter in response to TNFa
is mediated by NFkB, chromatin immunoprecipitation (ChIP)
studies were performed using a specific anti-p65 antibody, or
preimmune serum in THP-1 cells. No amplification of the
CXCL5 promoter was observed when nonspecific antibodies
were used to immunoprecipitate the chromatin (IgG, Figure 7G),
whereas a specific fragment corresponding to the NFkB binding
site of the CXCL5 promoter was amplified when chromatin
of TNFa-treated cells was immunoprecipitated with an anti-
NFkB antibody (Figure 7G). Furthermore, rosiglitazone treatment
resulted in decreased binding of p65 to this site, which was
consistent with the transfection data (Figure 7F). Altogether,
these results suggest that TNFa triggers the expression of
CXCL5 in WAT through the NFkB pathway.
DISCUSSION
The most important finding in this study is the insulin sensitizing
effects of both anti-CXCL5 neutralizing antibodies and CXCR2344 Cell Metabolism 9, 339–349, April 8, 2009 ª2009 Elsevier Inc.
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CXCL5 and Insulin ResistanceFigure 6. CXCR2/ Mice Improve Insulin Sensitivity
(A and B) Fasting glucose (A) and insulin (B) in 10-week-old CXCR2/ and control mice before (chow) and after 7 weeks of high fat diet (HFD) (n = 10 mice per
group).
(C) Body weight in control and CXCR2/ mice in chow and high fat diet.
(D) Food intake in control and CXCR2/ mice.
(E and F) Glucose clearance after intraperitoneal injection of insulin (E) or glucose (F) in control and CXCR2/ mice under chow or high-fat diet. Area under the
curve was analyzed (AUC). Data are means ± SEM.antagonists. This finding underscores a role of WAT-secreted
CXCL5 in the development of insulin resistance in obese subjects,
and validates an anti-CXCL5 therapy for the treatment or preven-
tion of obesity-induced insulin resistance.
WAT participation in metabolic control goes beyond its well-
known task as a lipid storage organ. Two major physiological
functions of WAT account for this participation. First, under
normal conditions WAT participates in the clearance of circu-
lating TG and FFA. Increased circulating FFA, such as observed
during obesity, leads to accumulation of TG in non-WATs, such
as muscle, liver, or pancreas, resulting in decreased glucose utili-
zation in these tissues and pancreatic toxicity, finally leading to
insulin resistance and diabetes (Waki and Tontonoz, 2007). The
second major role of WAT in the control of metabolism is the
secretion of adipose tissue-derived factors, such as leptin, resis-
tin, adiponectin, or TNFa, which may have both paracrine and
endocrine effects on several biological functions including
energy homeostasis, lipid and glucose metabolism, insulin sensi-
tivity, and inflammation (reviewed in Badman and Flier, 2007;
Rosen and Spiegelman, 2006). Obesity is characterized by
progressive macrophage infiltration in WAT, which is positively
correlated with insulin resistance (Clement et al., 2004; Di Gre-
gorio et al., 2005; Weisberg et al., 2003; Wellen and Hotamisligil,
2005). Although the relative contribution of macrophages,
compared to the contribution of adipocytes, to the development
of obesity-related insulin resistance is still not clear, recent
studies have underscored the important role of macrophage-secreted cytokines in insulin resistance (Wellen and Hotamisligil,
2005). Such is the case for the well-known effects of TNFa, IL-6,
MCP-1, or IL-1b (reviewed in Waki and Tontonoz, 2007; Wellen
and Hotamisligil, 2005). More recently, MCP-1 cytokine and its
receptor CCR2 have been shown to play a major role in macro-
phage infiltration in WAT and in the development of diabetes
(Sartipy and Loskutoff, 2003; Takahashi et al., 2003). Reduced
macrophage accumulation, as observed in CCR2 receptor-defi-
cient mice results in increased insulin sensitivity in these mice
(Weisberg et al., 2006). A recent study demonstrated, however,
that the absence of MCP-1 does not attenuate obesity-associ-
ated macrophage recruitment into WAT or improve metabolic
function, suggesting that MCP-1 is not critical for obesity-
induced insulin resistance (Inouye et al., 2007). The dominant
factor for macrophage recruitment to WAT and signaling to
insulin sensitive tissues remains, therefore, to be identified.
CXCL5 could be from our data one of these macrophage recruit-
ment and insulin desensitizing WAT-secreted factors. In our
study, we have demonstrated increased expression of CXCL5,
which is a WAT-secreted cytokine in obese human and mice.
Similar to other adipokines, CXCL5 is expressed mainly in the
macrophage fraction of WAT, and its role goes beyond the partic-
ipation in the typical local inflammatory reaction that is character-
istic of WAT in obese subjects. Interestingly, we show that TNFa,
which is secreted by both macrophages and adipocytes from
WAT in obesity, controls the expression of CXCL5 in mouse
and human. No CXCL5 regulation could be identified in Thp-1Cell Metabolism 9, 339–349, April 8, 2009 ª2009 Elsevier Inc. 345
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CXCL5 and Insulin ResistanceFigure 7. CXCL5 Expression Is Regulated by TNFa and Rosiglitazone
(A) CXCL5 level in conditioned medium of human subcutaneous adipose tissue explants after treatment with vehicle (control) or TNFa (10 ng/ml) for 24 hr (n = 3 per
group).
(B) Quantification of relative CXCL5 mRNA levels in WAT from obese ob/ob TNFa receptor / mice compared to the control obese mice (n = 3 per group).
(C and D) CXCL5 levels in WAT (A) from C57Bl/6 mice or THP1 macrophages (B) after treatment with vehicle (control), TNFa (10 ng/ml), rosiglitazone (106 M) or
cotreated with TNFa/rosiglitazone for 6 hr. Secreted CXCL5 in medium was analyzed by ELISA and normalized by DNA tissue content.
(E) Q-PCR analysis of CXCL5 mRNA in THP-1 macrophages treated as in (C).
(F) Luciferase activity expressed as relative luciferase units of a 1422 bp DNA fragment of the CXCL5 promoter coupled to the luciferase gene in the absence or in
the presence of a PPARg expression vector in 293T cells treated with vehicle, TNFa (10ng/ml), rosiglitazone (106 M) or both TNFa/rosiglitazone. Results were
normalized to b-galactosidase activity. Values in (C), (D), (E), and (F) represent means of three independents experiments.
(G) ChIP analysis of the NFkB binding site of the CXCL5 promoter in immunoprecipitated chromatin from THP-1 macrophages either nontreated (cont.) or treated
with TNFa, rosi, or a combination of both (upper panel). Chromatin was immunoprecipitated with mock antibody (IgG) or anti p65 antibody as indicated. Quan-
tification of the ChIP analysis in lower panel. Image J software was used to measure the optical density of the bands. Results are corrected by the signal of the
corresponding input lanes. Blot is representative of two independents experiments. Data are means ± SEM.macrophages upon treatment with sex steroids, dexametha-
sone, IBMX, saturated FFA, or unsaturated FFA (Figure S7).
Moreover, deletion of TNFa receptor in WAT from obese mice
abolished CXCL5 mRNA expression in this tissue, proving that
TNFa is a master regulator of CXCL5 during obesity. In addition,
this suggests that CXCL5 mediates the effects of TNFa on insulin
resistance. Thiazolidinediones, which are PPARg agonists used
clinically as insulin sensitizers, reduce CXCL5 expression, likely
through direct reduction of NFkB transcriptional regulation of
CXCL5 promoter in response to TNFa stimulation. This is consis-
tent with previously reported effects of PPARg in the inhibition of
the NFkB pathway (Ricote et al., 1998).
Our results show that CXCL5 promotes insulin resistance. This
is supported by the following data: first, increased circulating
CXCL5 in human obese subjects correlates with increased insulin
resistance; second, amelioration of insulin sensitivity, such as
observed during a very low calorie diet in human obese subjects,
or as a response to rosiglitazone treatment in mice, correlates
with decreased levels of CXCL5; third, CXCL5 impairs glucose346 Cell Metabolism 9, 339–349, April 8, 2009 ª2009 Elsevier Inc.uptake in isolated muscles; fourth, treatment of obese, insulin-
resistant mice with anti-CXCL5 blocking antibodies results in
modest but consistent amelioration of insulin sensitivity in these
mice; finally, and most importantly, CXCR2(/) mice show
improved insulin sensitivity and are resistant to diet-induced
insulin resistance and diabetes.
These effects of CXCL5 are not related, or at least not only
related, to neutrophil migration or the control of local inflamma-
tory reaction in WAT. CXCL5 function is rather related to the nega-
tive modulation of the insulin signaling pathway in distant muscle
cells. In line with this hypothesis is the observation that CXL5
inhibits Akt phosphorylation in isolated muscles in response to
insulin, which correlates with decreased glucose uptake in these
CXCL5-treated muscle cells. This decrease of insulin-induced
phospho-Akt is the result of the activation of the Jak2/STAT5
pathway by CXCL5 and the induction of SOC2 expression, which
is well known to inhibit insulin signaling (Starr et al., 1997). The
effects of CXCL5 in muscle are likely mediated by the CXCR2
receptor. This is consistent with the insulin sensitizing effects
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antagonists. Interestingly, this receptor is expressed in cells other
than muscle cells (such as endothelial, pulmonary, or intestinal
epithelial cells), suggesting that increased CXCL5 circulating
levels (such as observed in obesity) could be involved in the
development of obesity-related pathologies other than insulin
resistance (such as atherosclerosis and other inflammatory
diseases). Studies aiming to elucidate the role of WAT-secreted
CXCL5 in all these obesity-related pathologies are likely to be
forthcoming in the near future. Inhibiting CXCL5 secretion or
function in obese individuals not only ameliorate their insulin
sensitivity but could also decrease the risk of developing other
major obesity-related pathologies. Inhibition of CXCL5 signaling
should be therefore considered as a therapeutic tool for the treat-
ment of the metabolic syndrome.
EXPERIMENTAL PROCEDURES
Materials
All chemicals, except if stated otherwise, were purchased from Sigma (St.
Louis, MO). Recombinant human TNFa and recombinant mouse CXCL5
were purchased from AbCys SA (France) and R&D Systems (France), respec-
tively. Rosiglitazone was purchased from Molekula (France).
Animals and Experimental Design
Male ob/ob mice, male db/db mice and male C57BL/6 mice were purchased at
8–9 weeks of age from Charles River Laboratory. Male CXCR2/ mice were
purchased at 9 weeks of age from Jackson Laboratory. Animals were maintained
according to European Union guidelines for use of laboratory animals. In vivo
experiments were performed in compliance with the French guidelines for exper-
imental animal studies (Agreement No. B-34-172-27). For the diet-induced
obesitymodel, 6-week-old C57BL/6mice were fedad libitumwith a diet including
45% from fat (TestDiet) for 12 weeks. For antibody treatment, the neutralizing
CXCL5 antibody we purchased from Dr. Strieter and injected every day to every
other day as described previously (Arenberg et al., 1998). The neutralizing CXCL5
antibody has been shown to inhibit rat peritoneal neutrophil recruitment to
recombinant CXCL5 in vivo (Halloran et al., 1999). For antagonist treatment,
SB225002 was synthetized as previously described (White et al., 1998) and
injected in intraperitoneal everyday for 9 days (100mg/kg). For rosiglitazone treat-
ment, 11-week-old db/dbmice were gaved with 20 mg/kg everyday for 12 days.
Bodyweights andglycemiawasmeasuredevery 3days,andbloodsampleswere
collected. Food intake was measured every second day for 6 consecutive days.
For serum preparation, blood samples were collected. The blood let to clot
for at least 30 min before centrifugation for 10 min at 1000 3 g.
For glucose tolerance test, 18 hr fasted mice were injected i.p. with glucose
(1.7g/kg)andglycemiawere measuredat time 0,30, 60,and90minafter injection.
For insulin tolerance test, 8hr fastedmicewere injected i.p. with insulin (0.75U/kg)
and glucose level was measured at time 0, 20, and 40 min after injection.
Human Studies
Serum sample, and subcutaneous abdominal WAT were obtained from
subjects in agreement with French, Czech, and English laws on biomedical
research. Human adipocytes in primary culture were differentiated as
described (Tiraby et al., 2003). The different cell types of human subcutaneous
WAT were isolated as previously described (Curat et al., 2006). Human white
adipose tissue was isolated as described (Tiraby et al., 2003). Results are
expressed in pg/ml/g of tissue.
WAT Explants Culture
Fat pads from male C57BL/6 mice and/or db/db mice were dissected under
sterile conditions, washed in Krebs Ringer Bicarbonate HEPES buffer
(KRBH), minced finely, and incubated in 12-well tissue culture plates contain-
ing KRBH supplemented with 1% bovine serum albumin (BSA). The fat tissue
samples were left unstimulated at 37C under 5% CO2 for indicated time or
were stimulated with vehicle (DMSO), TNFa (10 ng/ml), rosiglitazone (106 M)or cotreated with TNFa/rosiglitazone. At different time point, conditioned
medium was removed and CXCL5 was measured by ELISA assay. At the
end of experiment, fat tissue was removed and DNA extraction was done to
normalize. Results are expressed in pg/ml/cells.
Protein Extraction
WAT, liver, and muscle were removed from C57BL/6 mice and were homoge-
nized by Polytron in TEG buffer (10 mM Tris-Hcl, pH 7.4, 1.5 mM EDTA, and
10% glycerol) containing protease inhibitors cocktail (Roche). The mixture
was then sonicated, and the cellular debris were pelleted by centrifugation
at 13,000 g for 10 min at 4C. CXCL5 level was analyzed by ELISA assay.
ELISA and Bio-Plex Assay
CXCL5 concentration in cellular extracts conditioned medium and serum was
determined by ELISA with Duoset kit (DY254 and DY443, R&D Systems) as
recommended by the manufacturer. CXCL1 and CXCL2 concentrations in
serum were evaluated by Bio-Plex Cytokine Assay (Bio-Rad) as recommended
by the manufacturer.
RNA Extraction and Reverse Transcriptase, Quantitative PCR
Total RNA from cells and tissues were isolated with TRIzol reagent (Invitrogen)
as described by the manufacturer. Reverse transcription was performed using
5 mg total RNA, random primers and MMLV enzyme (Invitrogen). Quantitative
PCR was performed with FastStart DNA Master SYBR Green I kit (Roche,
Manheim, Germany) on a Light Cycler instrument (Roche) as specified by
the manufacturer. Ribosomal protein S9 (rS9) was used as an internal control.
The sequence of the primers used is available upon request.
Cell Culture, Transient Transfection, and Glucose Transport
Preadipocytes 3T3-L1 cells were grown in DMEM supplemented with 10% fetal
bovine serum (FBS), 100 U/ml penicillin and 100 mg/ml streptomycin. 3T3-L1
cells were differentiated as previously described (Sarruf et al., 2005). To analyze
CXCL5 effect on adipocyte differentiation, 3T3-L1 preadipocytes were differ-
entiated with mix supplemented with recombinant mouse CXCL5 (50 ng/ml).
Glucose transport experiments were performed as previously described
(Abella et al., 2005). Human monocytic cell line Thp-1 were grown in RPMI
1640 supplemented with 10% FBS, 100 U/ml penicillin and 100 mg/ml
streptomycin. Macrophage differentiation was induced by stimulating cells
with TPA 100 nM for 48 hr. Then, macrophages Thp-1 were maintained in
DMEM 10% FBS and stimulated or not with TNFa (10 ng/ml), rosiglitazone
(106 M) or cotreated with TNFa /rosiglitazone for 18 hr. CXCL5 mRNA level
was analyzed by Q-PCR. Secreted CXCL5 was measured by ELISA assay
and normalized by DNA content. Fibroblastic 293T cells were grown in Dulbec-
co’s Modified Eagle’s Medium (DMEM) supplemented with 10% FBS, 100 U/ml
penicillin, and 100 mg/ml streptomycin. Transient transfections were per-
formed as described previously (Annicotte et al., 2005), and luciferase activity
measurements were normalized for b-galactosidase activity to correct for
differences in transfection efficiency. Graph values represent the mean of three
independent experiments.
Primary MEFs were obtained from embryos at day 13.5 as previously
described (Abella et al., 2005)and maintained in DMEM supplemented with
25 mM glucose and 10% FBS. MEFs were starved 1 hr in DMEM containing
0.2% BSA and then treated 30 min with Jak2 inhibitor AG490 (50 mM) or
CXCR2 antagonist SB225002 (106 M) before to stimulate 1 hr with CXCL5
(300 ng/ml). For insulin signaling, cells were stimulated with insulin (109 M)
for 10 min.
ChIP
ChIP assays were performed as described previously (Annicotte et al., 2006).
Briefly, proteins from Thp-1 cells were formaldehyde crosslinked to DNA.
After homogenization, lysis, and DNA sonication, proteins were then immuno-
precipitated using anti-p65 antibody. After washing, DNA-protein complexes
were subsequently eluted and crosslinking was reversed by heating the
samples at 65C for 16 hr. DNA was then purified using QIAGEN PCR purifica-
tion kit (QIAGEN, Courtabœuf, France) and PCR amplification was performed
using cxcl5 promoter-specific oligonuleotide primers.Cell Metabolism 9, 339–349, April 8, 2009 ª2009 Elsevier Inc. 347
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Human CXCL5 promoter corresponding to1359/+63 was cloned from breast
cancer cell line MCF-7 using 50-TCA GAA CCA GCC AGA AGA GGA-30 and
50-AGC GGA GAT TGG AGG AGC GAA GAT-30 and subcloned in xp-2 lucif-
erase reporter vector. CMV-GAL corresponds to the b-galactosidase gene
under the control of the cytomegalovirus (CMV) promoter.
Statistical Analysis
Data are presented as means ± SEM. Group means were compared by facto-
rial analysis of variance (ANOVA). Upon significant interactions, differences
between individual group means were analyzed by Fisher’s protected least-
squares difference (PLSD) test. Differences were considered statistically
significant at p < 0.05 (*), 0.01% p% 0.001 (**), p% 0.001 (***).
In human studies, statistical comparisons were performed using nonpara-
metric Wilcoxon-Mann Whitney test (p values < 0.05 were considered to be
statistically significant).
SUPPLEMENTAL DATA
Supplemental Data include two tables and seven figures and can be found online
at http://www.cell.com/cellmetabolism/supplemental/S1550-4131(09)00062-X.
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